AstraZeneca opens two new UK labs
Anglo-Swedish drug major AstraZeneca has opened two major scientific laboratories in the UK constructed at a combined cost of L76.0 million ($143.5 million) which. it added, represents its largest investment expenditure in the country to date.
The L60.0 million Cancer Research Area Building at Alderly Park in Cheshire, the opening of which was presided over by Dame Nancy Rothwell, vice president for research at Manchester University, is intended to increase the firm's candidate drug output, particularly in the field of oncology.
The second laboratory, which is located at the company's Charnwood research site in Loughborough in Leicestershire, cost L16.0 million to establish and can accommodate 75 scientists who will focus on the integration of safety assessments and drug discovery.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze